



**Sterne Kessler
Goldstein Fox**
ATTORNEYS AT LAW



Robert Greene Sterne
Edward Kessler
Jorge Goldstein
David K.S. Cornwell
Robert W. Esmond
Roy-Gene G. Durkin
Michele A. Cimbala
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
Steven R. Ludwig
John M. Covert
Linda E. Alcom
Robert C. Millonig
Lawrence B. Bugaisky
Donald J. Featherstone
Michael V. Messinger

Judith U. Kim
Timothy J. Shea, Jr.
Patrick E. Garrett
Jeffrey T. Helvey
Heidi L. Kraus
Albert L. Ferro*
Donald R. Banowitz
Peter A. Jackman
Teresa U. Medler
Jeffrey S. Weaver
Kendrick P. Patterson
Vincent L. Capuano
Eldora Ellison Floyd
Thomas C. Fiala
Brian J. Del Buono
Virgil Lee Beaton
Theodore A. Wood
Elizabeth J. Haanes

Joseph S. Ostroff
Frank R. Cottingham
Christine M. Uhliet
Rae Lynn Prengaman
George S. Bardmesser
Daniel A. Klein*
Jason D. Eisenberg
Michael D. Specht
Andrea J. Kamage
Tracy L. Muller*
LuAnne M. DeSantis
Ann E. Summerfield
Tiera S. Coston
Aric W. Ledford*
Helene C. Carlson
Timothy A. Doyle*
Jessica L. Parezo
Gaby L. Longworth*

Lori A. Gordon*
Nicole D. Dretar*
Ted J. Ebersole
Jyoti C. Iyer*
Laura A. Vogel

Registered Patent Agents*
Karen R. Markowicz
Nancy J. Leith
Matthew J. Dowd
Aaron L. Schwartz
Katrina Yujian Pei Quach
Bryan L. Skelton
Robert A. Schwartzman
Teresa A. Colella
Jeffrey S. Lundgren
Victoria S. Rutherford
Michelle K. Holoubek

Robert H. DeSelms
Simon J. Elliott
Julie A. Heider
Mita Mukherjee
Scott M. Woodhouse
Michael G. Penn
Christopher J. Walsh

Of Counsel
Kenneth C. Bass III
Evan R. Smith
Marvin C. Guthrie

*Admitted only in Maryland
*Admitted only in Virginia
*Practice Limited to
Federal Agencies

July 29, 2004

WRITER'S DIRECT NUMBER:

(202) 772-8673

INTERNET ADDRESS:

JCOVERT@SKGF.COM

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Art Unit 1614

Re: U.S. Utility Patent Application
Application No. 10/802,765; Filed: March 18, 2004
For: **Aryl Substituted Thiazinidinones and the Use Thereof**
Inventors: SUN *et al.*
Our Ref: 1861.1420003/JMC/RHD

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Information Disclosure Statement; and
2. 18 pages of Form PTO-1449 citing 76 documents.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

John M. Covert

John M. Covert
Attorney for Applicants
Registration No. 38,759

JMC/RHD:cpn
Enclosures

293576_1.DOC



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SUN *et al.*

Appl. No.: 10/802,765

Filed: March 18, 2004

For: **Aryl Substituted Thiazinidinones
and the Use Thereof**

Confirmation No.: 4695

Art Unit: 1614

Examiner: *To be assigned*

Atty. Docket: 1861.1420003/JMC/RHD

Information Disclosure Statement

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Copies of documents AK1, AA2, AB2, and AC2 are not provided in accordance with the U.S. Patent and Trademark Office pre-OG notice of July 11, 2003, which states "[t]he Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003."

Copies of the remaining documents were previously cited by or submitted to the Office in an IDS that complies with 37 C.F.R. § 1.98(a)-(c) in Application No. 10/195,530, filed July 16, 2002, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of the documents are not attached. 37 C.F.R. § 1.98(d).

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicant has listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicant reserves the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.


This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.




John M. Covert
Attorney for Applicants
Registration No. 38,759

Date: July 29, 2004

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT


 PATTY. DOCKET NO.
 21861.1420003/JMC/RHD

 APPLICATION NO.
 10/802,765

 APPLICANT
 SUN et al.

 FILING DATE
 March 18, 2004

 GROUP
 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1	3,309,377	10/19/1964	Surrey			03/14/1967
	AB1	3,377,355	04/09/1968	Surrey			06/30/1967
	AC1	4,933,453	06/12/1990	Hrib et al.			10/31/1989
	AD1	5,061,720	10/29/1991	Walsh et al.			09/13/1989
	AE1	5,229,388	07/20/1993	Hrib et al.			11/21/1991
	AF1	6,335,354 B2	01/01/2002	Hogenkamp			03/29/2001
	AG1	2002/0006947 A1	01/17/2002	Hogenkamp et al.			03/22/2001
	AH1	2002/0040025 A1	04/04/2002	Hogenkamp et al.			03/12/2001
	AI1	6,414,011 B1	07/02/2002	Hogenkamp et al.			03/24/2000
	AJ1	2003/0055088 A1	03/20/2003	Shao et al.			09/06/2002
	AK1	2003/0109521 A1	06/12/2003	Sun et al.			07/16/2002

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL1	EP 0 292 305 A1	11/23/1988	Europe			Yes No
	AM1	EP 0 705 816 A1	04/10/1996	Europe			Yes No
	AN1	WO 99/62891 A1	12/09/1999	WIPO			Yes No
	AO1	DE 22 59 222	06/20/1973	Germany			Yes No
	AP1	GB 1 409 898	10/15/1975	Great Britain			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>1</u>	Andres, C.J., et al., "4-Thiazolidinones: Novel Inhibitors of the Bacterial Enzyme MurB," <i>Bioorg. Med. Chem. Lett.</i> 10:715-717, Pergamon Press (2000)
	AS	<u>1</u>	Bartoszyk, G.D., et al., "Ralitoline: a thiazolidinone," <i>Curr. Probl. Epilepsy</i> 4:309-311, John Libbey (1986)
	AT	<u>1</u>	Bhat, A.R., et al., "Synthesis and Biological Activity of Some 3-(1,3,4-oxadiazol-2-yl)-2-aryl-4-thiazolidinones," <i>Indian Drugs</i> 21:129-134, Indian Drug Manufacturers' Association (1984)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 1861.1420003/JMC/RHD	APPLICATION NO. 10/802,765
	APPLICANT SUN et al.	
	FILING DATE March 18, 2004	GROUP 1614

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA2	6,737,418 B2	05/18/2004	Hogenkamp et al.			04/30/2002
	AB2	2003/0073724 A1	04/17/2003	Shao et al.			09/06/2002
	AC2	2003/0236273 A1	12/25/2003	Goehring, et al.			03/13/2003
	AD2						
	AE2						
	AF2						
	AG2						
	AH2						
	AI2						
	AJ2						
	AK2						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL2	EP 0 524 595 A1	01/27/1993	Europe			Yes No
	AM2	EP 0 699 675 A2	03/06/1996	Europe			Yes No
	AN2	WO 00/57877 A1	10/05/2000	WIPO			Yes No
	AO2	WO 00/63197 A1	10/26/2000	WIPO			Yes No
	AP2						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>2</u>	Bensimon, G., et al., "A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis," <i>New Engl. J. Med.</i> 330:585-591, Massachusetts Medical Society (1994)
	AS	<u>2</u>	Brown, C.M., et al., "Neuroprotective properties of lifarizine compared with those of other agents in a mouse model of focal cerebral ischaemia," <i>British J. Pharmacol.</i> 115:1425-1432, Stockton Press (1995)
	AT	<u>2</u>	Buchan, A.M., et al., "AMPA Antagonists: Do They Hold More Promise for Clinical Stroke Trials Than NMDA Antagonists?" <i>Stroke Suppl. I</i> 24:I-148-I-152, American Heart Association (1993)
EXAMINER			DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1861.1420003/JMC/RHD	APPLICATION NO. 10/802,765
	APPLICANT SUN et al.	
	FILING DATE March 18, 2004	GROUP 1614

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA3						
	AB3						
	AC3						
	AD3						
	AE3						
	AF3						
	AG3						
	AH3						
	AI3						
	AJ3						
	AK3						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL3						Yes No
	AM3						Yes No
	AN3						Yes No
	AO3						Yes No
	AP3						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>3</u>	Capan, G., et al., "Synthesis and Anticonvulsant Activity of New 3-[(2-furyl)carbonyl]amino-4-thiazolidinone and 2-[(2-furyl)carbonyl]hydrazono-4-thiazoline Derivatives," <i>Il Farmaco</i> 51:729-732, Societa Chimica Italiana (1996)
	AS	<u>3</u>	Catterall, W.A., "Neurotoxins that Act on Voltage-Sensitive Sodium Channels in Excitable Membranes," <i>Ann. Rev. Pharmacol. Toxicol.</i> 20:15-43, Annual Reviews, Inc. (1980)
	AT	<u>3</u>	Catterall, W.A., "Common modes of drug action on Na ⁺ channels: local anesthetics, antiarrhythmics and anticonvulsants," <i>Trends Pharmacol. Sci.</i> 8:57-65, Elsevier Science B.V. (1987)
EXAMINER			DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 1861.1420003/JMC/RHD	APPLICATION NO. 10/802,765
	APPLICANT SUN et al.	
	FILING DATE March 18, 2004	GROUP 1614

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA4						
	AB4						
	AC4						
	AD4						
	AE4						
	AF4						
	AG4						
	AH4						
	AI4						
	AJ4						
	AK4						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL4						Yes No
	AM4						Yes No
	AN4						Yes No
	AO4						Yes No
	AP4						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
AR	<u>4</u>	Catterall, W.A., "Structure and Function of Voltage-Sensitive Ion Channels," <i>Science</i> 242:50-61, American Association for the Advancement of Science (1988)	
AS	<u>4</u>	Cesur, N., et al., "New Acylthiosemicarbazides, Thiazolidinones, and 1,3,4-Oxadiazoles as Possible Anticonvulsants," <i>Arch. Pharm. (Weinheim, Ger.)</i> 325:623-624, VCH Verlagsgesellschaft mbH (1992)	
AT	<u>4</u>	Creveling, C.R., et al., "Batrachotoxin-Induced Depolarization and [³ H]Batrachotoxinin-A 20 α -Benzoate Binding in a Vesicular Preparation from Guinea Pig Cerebral Cortex," <i>Mol. Pharmacol.</i> 23:350-358, The American Society for Pharmacology and Experimental Therapeutics (1983)	
EXAMINER			DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 1861.1420003/JMC/RHD	APPLICATION NO. 10/802,765
	APPLICANT SUN et al.	
	FILING DATE March 18, 2004	GROUP 1614

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA5						
	AB5						
	AC5						
	AD5						
	AE5						
	AF5						
	AG5						
	AH5						
	AI5						
	AJ5						
	AK5						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL5						Yes No
	AM5						Yes No
	AN5						Yes No
	AO5						Yes No
	AP5						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
AR	<u>5</u>	Denicoff, K.D., et al., "Efficacy of Carbamazepine Compared With Other Agents: A Clinical Practice Survey," <i>J. Clin. Psychiatry</i> 55:70-76, Physicians Postgraduate Press (1994)	
AS	<u>5</u>	Donaldson, I., "Tegretol: A double blind trial in tinnitus," <i>J. Laryngol. Otol.</i> 95:947-951, Headley Brothers (1981)	
AT	<u>5</u>	El-Meligie, S., "Synthesis of Certain Thiazolidinone Derivatives as Possible Anticonvulsants," <i>Bull. Fac. Pharm. Cairo Univ.</i> 28:35-37, Cairo University (1990)	
EXAMINER			DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 1861.1420003/JMC/RHD	APPLICATION NO. 10/802,765
	APPLICANT SUN et al.	
	FILING DATE March 18, 2004	GROUP 1614

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA6						
	AB6						
	AC6						
	AD6						
	AE6						
	AF6						
	AG6						
	AH6						
	AI6						
	AJ6						
	AK6						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL6						Yes No
	AM6						Yes No
	AN6						Yes No
	AO6						Yes No
	AP6						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>6</u>	El-Shafei, A.K., and Hassan, K.M., "Synthesis of Some New N-Oxidopyridylthiazolidin-4-ones," Curr. Sci. 52:633-635, Current Science Association (1983)
	AS	<u>6</u>	Ergenc, N., and Capan, G., "Synthesis and Anticonvulsant Activity of New 4-Thiazolidone and 4-Thiazoline Derivatives," Il Farmaco 49:449-451, Societa Chimica Italiana (1994)
	AT	<u>6</u>	Fischer, W., et al., "Anticonvulsant and sodium channel blocking effects of ralitoline in different screening models," Naunyn-Schmiedeberg's Arch. Pharmacol. 346:442-452, Springer-Verlag (1992)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 1861.1420003/JMC/RHD	APPLICATION NO. 10/802,765
	APPLICANT SUN <i>et al.</i>	
	FILING DATE March 18, 2004	GROUP 1614

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA7						
	AB7						
	AC7						
	AD7						
	AE7						
	AF7						
	AG7						
	AH7						
	AI7						
	AJ7						
	AK7						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL7						Yes No
	AM7						Yes No
	AN7						Yes No
	AO7						Yes No
	AP7						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>7</u>	Gahane, D.R., et al., "Mannich Reaction Products of 5-Arylidene-2-phenylimino-4-thiazolidinones as Anticonvulsants," <i>Indian J. Pharm. Sci.</i> 60:275-279, Indian Pharmaceutical Association (1998)
	AS	<u>7</u>	Gaikwad, N.J., and Agrawal, S.B., "Substituted 4-Thiazolidinones as Anticonvulsants VII," <i>Indian Drugs</i> 34:542-543, Indian Drug Manufacturers' Association (1997)
	AT	<u>7</u>	Gaikwad, N.J., and Tirpude, R.N., "Substituted 4-Thiazolidinones as Anticonvulsants V," <i>Indian Drugs</i> 31:593-594, Indian Drug Manufacturers' Association (1994)
EXAMINER			DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1861.1420003/JMC/RHD	APPLICATION NO. 10/802,765
	APPLICANT SUN <i>et al.</i>	
	FILING DATE March 18, 2004	GROUP 1614

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA8						
	AB8						
	AC8						
	AD8						
	AE8						
	AF8						
	AG8						
	AH8						
	AI8						
	AJ8						
	AK8						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL8						Yes No
	AM8						Yes No
	AN8						Yes No
	AO8						Yes No
	AP8						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
AR	<u>8</u>	Gaikwad, N.J., and Shah, K., "Substituted 4-Thiazolidinones as Anticonvulsants IV," <i>Indian Drugs</i> 26:341-342, Indian Drug Manufacturers' Association (1989)	
AS	<u>8</u>	Gaikwad, N.J., et al., "Substituted 4-Thiazolidinones as Anticonvulsants. III," <i>Indian Drugs</i> 24:288-289, Indian Drug Manufacturers' Association (1987)	
AT	<u>8</u>	Gaikwad, N.J., et al., "Substituted 4-Thiazolidinones as Anticonvulsants," <i>Indian Drugs</i> 23:384-385, Indian Drug Manufacturers' Association (1986)	
EXAMINER			DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 1861.1420003/JMC/RHD	APPLICATION NO. 10/802,765
	APPLICANT SUN <i>et al.</i>	
	FILING DATE March 18, 2004	GROUP 1614

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA9						
	AB9						
	AC9						
	AD9						
	AE9						
	AF9						
	AG9						
	AH9						
	AI9						
	AJ9						
	AK9						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL9						Yes No
	AM9						Yes No
	AN9						Yes No
	AO9						Yes No
	AP9						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>9</u>	Graham, S.H., et al., "Neuroprotective Effects of a Use-Dependent Blocker of Voltage-Dependent Sodium Channels, BW619C89, in Rat Middle Cerebral Artery Occlusion," <i>J. Pharmacol. Exp. Ther.</i> 269:854-859, Williams & Wilkins (1994)
	AS	<u>9</u>	Graham, S.H., et al., "A Dose-Response Study of Neuroprotection Using the AMPA Antagonist NBQX in Rat Focal Cerebral Ischemia," <i>J. Pharmacol. Exp. Ther.</i> 276:1-4, Williams & Wilkins (1996)
	AT	<u>9</u>	Gupta, R.C., et al., "Biologically Active Thiazolidinone," <i>J. Indian Chem. Soc.</i> 55:832-834, The Indian Chemical Society (1978)
EXAMINER			DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 1861.1420003/JMC/RHD	APPLICATION NO. 10/802,765
	APPLICANT SUN et al.	
	FILING DATE March 18, 2004	GROUP 1614

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA10						
	AB10						
	AC10						
	AD10						
	AE10						
	AF10						
	AG10						
	AH10						
	AI10						
	AJ10						
	AK10						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL10						Yes No
	AM10						Yes No
	AN10						Yes No
	AO10						Yes No
	AP10						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>10</u>	Hunskaar, S., et al., "Formalin test in mice, a useful technique for evaluating mild analgesics," <i>J. Neurosci. Methods</i> 14 :69-76, Elsevier Science B.V. (1985)
	AS	<u>10</u>	Husain, M.I., and Amir, M., "Synthesis of some new 2-arylimino-3-[p-(3,4,5-trimethoxybenzamido)benzoylamino]-thiazolid-4-ones as possible anticonvulsant agents," <i>Acta Pharm. Jugosl.</i> 35:167-173, Federation of Yugoslav Pharmaceutical Association (1985)
	AT	<u>10</u>	Iwasaki, Y., et al., "CNQX prevents spinal motor neuron death following sciatic nerve transection in newborn rats," <i>J. Neurological Sci.</i> 134:21-25, Elsevier Science B.V. (1995)
EXAMINER			DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			

<p>FORM PTO-1449</p> <p><u>INFORMATION DISCLOSURE STATEMENT</u></p>	ATTY. DOCKET NO. 1861.1420003/JMC/RHD	APPLICATION NO. 10/802,765
	APPLICANT SUN et al.	
	FILING DATE March 18, 2004	GROUP 1614

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA11						
	AB11						
	AC11						
	AD11						
	AE11						
	AF11						
	AG11						
	AH11						
	AI11						
	AJ11						
	AK11						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL11						Yes No
	AM11						Yes No
	AN11						Yes No
	AO11						Yes No
	AP11						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)		
AR	<u>11</u>	Koga, T., et al. , "The protective effects of CP-060S on ischaemia- and reperfusion-induced arrhythmias in anaesthetized rats," <i>Br. J. Pharmacol.</i> 123:1409-1417, Stockton Press (1998)
AS	<u>11</u>	Leff, P., and Dougall, I.G., "Further concerns over Cheng-Prusoff analysis," <i>Trends Pharmacol. Sci.</i> 14:110-112, Elsevier Science Publishers Ltd. (1993)
AT	<u>11</u>	Loscher, W., et al., "Ralitoline: A Reevaluation of Anticonvulsant Profile and Determination of 'Active' Plasma Concentrations in Comparison with Prototype Antiepileptic Drugs in Mice," <i>Epilepsia</i> 32:560-568, Raven Press, Ltd. (1991)
EXAMINER		DATE CONSIDERED
<p>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</p>		

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 1861.1420003/JMC/RHD	APPLICATION NO. 10/802,765
	APPLICANT SUN et al.	
	FILING DATE March 18, 2004	GROUP 1614

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA12						
	AB12						
	AC12						
	AD12						
	AE12						
	AF12						
	AG12						
	AH12						
	AI12						
	AJ12						
	AK12						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL12						Yes No
	AM12						Yes No
	AN12						Yes No
	AO12						Yes No
	AP12						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>12</u>	Majumdar, B., et al., "An electrocochleographic study of the effects of lignocaine on patients with tinnitus," <i>Clin. Otolaryngol.</i> 8:175-180, Blackwell Scientific Publications (1983)
	AS	<u>12</u>	Mishra, S., et al., "Synthesis of 5-arylidene-2-aryl-3-(phenothiazino/benzotriazoloacetamidyl)-1,3-thiazolidine-4-ones as antiinflammatory, anticonvulsant, analgesic and antimicrobial agents," <i>Indian. J. Chem.</i> 36B:826-830, Council Of Scientific And Industrial Research (1997)
	AT	<u>12</u>	Møller, A.R., "Similarities Between Chronic Pain and Tinnitus," <i>Am. J. Otol.</i> 18:577-585, Lippincott-Raven (1997)
EXAMINER			DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 1861.1420003/JMC/RHD	APPLICATION NO. 10/802,765
	APPLICANT SUN et al.	
	FILING DATE March 18, 2004	GROUP 1614

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA13						
	AB13						
	AC13						
	AD13						
	AE13						
	AF13						
	AG13						
	AH13						
	AI13						
	AJ13						
	AK13						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL13						Yes No
	AM13						Yes No
	AN13						Yes No
	AO13						Yes No
	AP13						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	13	Ohizumi, Y., et al., "Specific Inhibition of [³ H] Saxitoxin Binding to Skeletal Muscle Sodium Channels by Geographutoxin II, a Polypeptide Channel Blocker," <i>J. Biol. Chem.</i> 261:6149-6152, The American Society of Biological Chemists, Inc. (1986)
AS	13	Omar, A., et al., "Some Novel Theophylline Thiosemicarbazide and Thiazolidinone Derivatives as Potential Anticancer and Anticonvulsant Agents," <i>Pharmazie</i> 34:110-111, VEB Verlag Volk und Gesundheit (1979)
AT	13	Parmar, S.S., et al., "Substituted Thiazolidones and Their Selective Inhibition of Nicotinamide-Adenine Dinucleotide Dependent Oxidations," <i>J. Med. Chem.</i> 15:99-101, American Chemical Society (1972)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 1861.1420003/JMC/RHD	APPLICATION NO. 10/802,765
	APPLICANT SUN et al.	
	FILING DATE March 18, 2004	GROUP 1614

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA14						
	AB14						
	AC14						
	AD14						
	AE14						
	AF14						
	AG14						
	AH14						
	AI14						
	AJ14						
	AK14						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL14						Yes No
	AM14						Yes No
	AN14						Yes No
	AO14						Yes No
	AP14						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>14</u>	Ragab, F.A., et al., "Synthesis and anticonvulsant activity of new thiazolidinone and thioxoimidazolidinone derivatives derived from furochromones," <i>Pharmazie</i> 52:926-929, Govi-Verlag Pharmazeutischer Verlag GmbH (1997)
	AS	<u>14</u>	Ragab, F.A., et al., "Synthesis, Anticonvulsant and Antimicrobial Activities of Certain New Furochromones," <i>Egypt. J. Pharm. Sci.</i> 34:387-400, National Information And Documentation Center (1993)
	AT	<u>14</u>	Ragab, F.A., and Seif-El-Nasr, M., "Synthesis and Anticonvulsant Activity of Some Ureido Thiazolidinone and Thiohydantoin Derivatives of Furochromones," <i>Bull. Fac. Pharm.</i> 30:209-213, Cairo University (1992)
EXAMINER			DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 1861.1420003/JMC/RHD	APPLICATION NO. 10/802,765
	APPLICANT SUN et al.	
	FILING DATE March 18, 2004	GROUP 1614

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA15						
	AB15						
	AC15						
	AD15						
	AE15						
	AF15						
	AG15						
	AH15						
	AI15						
	AJ15						
	AK15						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL15						Yes No
	AM15						Yes No
	AN15						Yes No
	AO15						Yes No
	AP15						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>15</u>	Sheardown, M.J., et al., "AMPA, but not NMDA, receptor antagonism is neuroprotective in gerbil global ischaemia, even when delayed 24 h," <i>Eur. J. Pharmacol.</i> 236:347-353, Elsevier Science B.V. (1993)
	AS	<u>15</u>	Simpson, J.J., and Davies, W.E., "Recent advances in the pharmacological treatment of tinnitus," <i>Trends Pharmacol. Sci.</i> 20:12-18, Elsevier Science London (1999)
	AT	<u>15</u>	Singh, V.P., et al., "Thiazolidinones: A Review," <i>Asian J. Chem. Rev.</i> 3:12-21, Chemic Publishing Co. (1992)
EXAMINER			DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 1861.1420003/JMC/RHD	APPLICATION NO. 10/802,765
	APPLICANT SUN <i>et al.</i>	
	FILING DATE March 18, 2004	GROUP 1614

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA16						
	AB16						
	AC16						
	AD16						
	AE16						
	AF16						
	AG16						
	AH16						
	AI16						
	AJ16						
	AK16						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL16						Yes No
	AM16						Yes No
	AN16						Yes No
	AO16						Yes No
	AP16						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>16</u>	Srivastava, S.K., et al., "Synthesis of 5-arylidene-2-aryl-3-(2-chlorophenothiazinoacetamidyl)-1,3-thiazolidin-4-ones as antifungal and anticonvulsant agents," <i>J. Indian Chem. Soc.</i> 77:104-105, The Indian Chemical Society (February 2000)
	AS	<u>16</u>	Stys, P.K., et al., "Ionic Mechanisms of Anoxic Injury in Mammalian CNS White Matter: Role of Na ⁺ Channels and Na ⁺ -Ca ²⁺ Exchanger," <i>J. Neurosci.</i> 12:430-439, Society for Neuroscience (1992)
	AT	<u>16</u>	Taylor, C.P., and Meldrum, B.S., "Na ⁺ channels as targets for neuroprotective drugs," <i>Trends Pharmacol. Sci.</i> 16:309-316, Elsevier Science Ltd. (1995)
EXAMINER			DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 1861.1420003/JMC/RHD	APPLICATION NO. 10/802,765
	APPLICANT SUN et al.	
	FILING DATE March 18, 2004	GROUP 1614

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA17						
	AB17						
	AC17						
	AD17						
	AE17						
	AF17						
	AG17						
	AH17						
	AI17						
	AJ17						
	AK17						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL17						Yes No
	AM17						Yes No
	AN17						Yes No
	AO17						Yes No
	AP17						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>17</u>	Tonndorf, J., "The analogy between tinnitus and pain: A suggestion for a physiological basis of chronic tinnitus," <i>Hear. Res.</i> 28:271-275, Elsevier Science B.V. (1987)
	AS	<u>17</u>	Ulusoy, N., et al., "Synthesis and Anticonvulsant Activity of Some New Arylidenehydrazides and 4-Thiazolidinones," <i>Monatsh. Chem.</i> 127:1197-1202, Springer-Verlag (1996)
	AT	<u>17</u>	Woodward, R.M., et al., "Effects of Steroids on γ -Aminobutyric Acid Receptors Expressed in <i>Xenopus</i> Oocytes by Poly(A) ⁺ RNA from Mammalian Brain and Retina," <i>Mol. Pharmacol.</i> 41:89-103, Williams and Wilkins (1992)
EXAMINER			DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 1861.1420003/JMC/RHD	APPLICATION NO. 10/802,765
	APPLICANT SUN et al.	
	FILING DATE March 18, 2004	GROUP 1614

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA18						
	AB18						
	AC18						
	AD18						
	AE18						
	AF18						
	AG18						
	AH18						
	AI18						
	AJ18						
	AK18						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL18						Yes No
	AM18						Yes No
	AN18						Yes No
	AO18						Yes No
	AP18						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>18</u>	Wrathall, J.R., et al., "Amelioration of Functional Deficits from Spinal Cord Trauma with Systemically Administered NBQX, an Antagonist of Non-N-methyl-D-aspartate receptors," <i>Exp. Neurol.</i> 137:119-126, Academic Press, Inc. (1996)
	AS	<u>18</u>	International Search Report for International Patent Application No. PCT/US02/22367, mailed October 9, 2002.
	AT	<u>18</u>	
EXAMINER			DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			